SLC33A1 and Splenomegaly: Postmortem assessment showed that treatment was able to prevent all major phenotypic features of AT-1 sTg mice, namely loss of body fat (Fig. 4c), loss of bone mineral density (Fig. 4d), splenomegaly (Fig. 4e, f), lymphadenopathy (Fig. 4g, h), and tissue inflammation (Fig. 4i, j).